AI-native radiology company Raidium announced on Thursday the US launch of Raidium Read (R.Read), applying its AI-native imaging solution initially to oncology research centres.

Raidium has already been deployed at Moffitt Cancer Center, where it was selected to replace the legacy radiomics tool. The Raidium platform offers whole-body lesion detection, AI segmentation models, and longitudinal transfer of lesions across follow-up and prior studies, supporting complex oncology imaging workflows in clinical research settings, as a first demonstration of agentic AI applied to radiology.

R. Read is available now for clinical trial and oncology research use, with final regulatory clearance for clinical practice and care routines forthcoming, the company said. Raidium is pursuing 510(k) clearance for a subset of features and expects to announce clearance before year-end 2026. Cancer centres can get started immediately without integration prerequisites, reducing implementation friction and making the workflow easier to adopt in existing environments.